Based on what happened with the phase 2 data, don't expect PR as quickly with phase 3. They will check the numbers on everything to make darn sure it's totally accurate, including enrollment numbers and goals. The good news is MOS rates are already being established since the enrollment for this trial has extended as long as it has. End point data for the patients who enrolled at the beginning of the trial is already coming in. The FDA could look into the data anytime they please. The big question is how many patients enrolled in the first 3 months of this trial period? And the other big question is how many enrollees with end point data will it take for the FDA to approve the treatment? Since we don't know the answer to that first question, with each passing day it becomes exponentially more dangerous to be short on this stock.
Well put. Although taking a stance against the paid bashers isn't necessary. Reading their posts, which appear to be the childish rantings of a middle schooler, lack any kind of factual data. They usually remind me of a child stomping about the house trying to get revenge on their parents for not letting them have candy. They love touting the fact that PPHM is $1 per share as if it has any substance. Ford was $1 a share in 2009. I agree with you that the best and only chance of the bashers sounding remotely knowledgeable would be to attack the companies management eventhough I don't consider PPHM's management to be poor...just a lil rough around the edges and in need of some tweaking.
chemo has to be administered in a higher dose to toxify all cells in the effort to kill the cancer cells. if the cancer cells are modified by bavi (lipid exposure) the body can now attack the cell without chemo. The docetaxel is being used as an immune accelerator so to speak in these trials for stage IV patients. You have to wonder if any chemo of any kind would be needed at all for an early stage patient. The botched trial data used placebo, 1mg, and 3mg arm if I recall correctly. As long as bavi activates the lipid switch, the immune system can now recognize that cell as a problem. No treatment can do this without causing severe toxicity issues over long treatment periods and those treatments depend on the highly toxic chemicals to damage the cancer cells before the healthy cells. Bavi doesn't appear to have any effect on healthy cells.
Bavi doubled MOS for stage IV cancer patients (lung and breast) and has virtualy no toxicity. This is earth shattering, mountain moving, unheard of potential in comparison to current treatment methods. Everything available right now is highly toxic. Even if Bavi simply matched MOS, it is still better than current treatment plans hands down and the FDA knows this. With that layed out on the table, what can Bavi do for patients diagnosed with an early stage breast or lung cancer? Vaccine potential is there too. How much money do drug companies make from flu vaccines? Yeah that's just some of the icing on this cake. This trial is a formality and first look in results could be all it takes. The FDA is treating this as if it were toxic or had adverse side effects, but thus far, there aren't any. This will heavily weigh on how fast this gets approved. They could approve it right now and if there are any, monitor potential risks. Any first look in information provided to the FDA could change the game in an instant. Assuming that the trial must be completed before the FDA will approve it could be a fools bargain.